The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages

Julie Schulthess(Nuffield Orthopaedic Centre), Sumeet Pandey(John Radcliffe Hospital), Melania Capitani(John Radcliffe Hospital), Kévin Rue-Albrecht(University of Oxford), Isabelle C. Arnold(John Radcliffe Hospital), Fanny Franchini(University of Oxford), Agnieszka Chomka(University of Oxford), Nicholas E. Ilott(University of Oxford), Daniel Johnston(University of Oxford), Elisabete Pires(University of Oxford), James McCullagh(University of Oxford), Stephen N. Sansom(University of Oxford), Carolina V. Arancibia-Cárcamo(John Radcliffe Hospital), Holm H. Uhlig(John Radcliffe Hospital), Fiona Powrie(Nuffield Orthopaedic Centre)
Immunity
January 25, 2019
Cited by 994Open Access
Full Text

Abstract

Host microbial cross-talk is essential to maintain intestinal homeostasis. However, maladaptation of this response through microbial dysbiosis or defective host defense toward invasive intestinal bacteria can result in chronic inflammation. We have shown that macrophages differentiated in the presence of the bacterial metabolite butyrate display enhanced antimicrobial activity. Butyrate-induced antimicrobial activity was associated with a shift in macrophage metabolism, a reduction in mTOR kinase activity, increased LC3-associated host defense and anti-microbial peptide production in the absence of an increased inflammatory cytokine response. Butyrate drove this monocyte to macrophage differentiation program through histone deacetylase 3 (HDAC3) inhibition. Administration of butyrate induced antimicrobial activity in intestinal macrophages in vivo and increased resistance to enteropathogens. Our data suggest that (1) increased intestinal butyrate might represent a strategy to bolster host defense without tissue damaging inflammation and (2) that pharmacological HDAC3 inhibition might drive selective macrophage functions toward antimicrobial host defense.


Related Papers

No related papers found

Powered by citation graph analysis